Physician profile
David B Page
NPI 1922241140
$237,864.57
in general payments reported to CMS, 2019-2025
21 companies · $39K in 2025
The $39K reported for 2025 was more than what 93% of Medical Oncology providers received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $45K · 2020: $8,354 · 2021: $52K · 2022: $48K · 2023: $19K · 2024: $26K · 2025: $39K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $68K · Travel and Lodging: $11K · Food and Beverage: $3,888 · Long Term Medical Supply Or Device Loan: $1,696 · Education: $190.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $67,998.75 |
| Travel and Lodging | $10,520.56 |
| Food and Beverage | $3,887.97 |
| Long Term Medical Supply Or Device Loan | $1,696.38 |
| Education | $190.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $111,574.58 | 2019-2024 | Phesgo, Perjeta |
| Novartis Pharmaceuticals Corporation | $29,123.62 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $20,333.93 | 2019-2025 | Keytruda |
| Lilly USA, LLC | $17,082.93 | 2019-2023 | |
| Eli Lilly and Company | $14,948.89 | 2021-2025 | |
| Gilead Sciences, INC. | $9,208.91 | 2021-2025 | Trodelvy |
| Seagen INC. | $9,158.03 | 2021-2023 | Tukysa |
| Astrazeneca Pharmaceuticals LP | $7,714.30 | 2019-2025 | Enhertu |
| Stemline Therapeutics INC. | $7,633.42 | 2023-2025 | Orserdu |
| Daiichi Sankyo INC. | $5,106.30 | 2022-2025 | Enhertu |
| Pfizer INC. | $3,124.36 | 2024-2025 | |
| Genzyme Corporation | $2,115.00 | 2021 | |
| Astellas Pharma US INC | $184.94 | 2024 | |
| Genentech, INC. | $182.91 | 2022-2024 | Itovebi, Tecentriq |
| Caris Mpi, INC. | $162.40 | 2025 | Mi Cancer Seek |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $158.55 | 2019-2022 | |
| Incyte Corporation | $51.50 | 2022-2023 | Opzelura |
4 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Page listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.